Journals / Bezmiâlem Science / 2020 / Cilt: 8 - Sayı: 3

An Overview of COVID-19 Medicines in Current Guidelines

Güncel Kılavuzlardaki COVİD-19 İlaçlarına Bir Bakış

Pages
44–49
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, agents with potential efficacy againstCOVID-19 are presented in summary.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:An acute respiratory disease caused by a new coronavirus (Severeacute respirotary syndrome-coronavirüs-2, previously known as2019-nCoV), coronavirus disease 2019 (COVID-19), appearedin December 2019 and then has spread rapidly throughout theworld starting from China, Japan and South Korea.
📊
Key Findings & Data:As of January30, 2020, the World Health Organization has officially declaredthe COVID-19 outbreak.
💡
Conclusion & Impact:In this review, agents with potential efficacy againstCOVID-19 are presented in summary.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

An acute respiratory disease caused by a new coronavirus (Severeacute respirotary syndrome-coronavirüs-2, previously known as2019-nCoV), coronavirus disease 2019 (COVID-19), appearedin December 2019 and then has spread rapidly throughout theworld starting from China, Japan and South Korea. As of January30, 2020, the World Health Organization has officially declaredthe COVID-19 outbreak. Considering the clinical symptomsof COVID-19, it has many symptoms such as high fever, cough,and fatigue. It is reported that this disease is very severe and causesserious consequences such as cytokine storm and acute respiratorydistress syndrome in the elderly and those with chronic diseases.Currently, scientists are trying to find a specific antiviral treatmentstrategy. Various medications such as hydroxychloroquine, lopinavir/ ritonavir, ribavirin, remdesivir and favipiravir are currently beingapplied in clinical trials to test their efficacy and safety worldwidein COVID-19 treatment, and some promising results have beenachieved so far. In this review, agents with potential efficacy againstCOVID-19 are presented in summary.

Özet

Yeni bir koronavirüsün (daha önce 2019-nCoV olarak bilinenŞiddetli akut solunum enfeksiyonu-koronavirüs-2) nedenolduğu akut solunum yolu hastalığı, koronavirüs hastalığı 2019(COVİD-19) Aralık 2019’da ortaya çıkmış ve daha sonra Çin,Japonya ve Güney Kore’den başlayarak Dünya genelinde hızlıbir yayılım göstermiştir. 30 Ocak 2020 itibariyle de DünyaSağlık Örgütü COVİD-19 salgınını resmi olarak ilan etmiştir.COVİD-19’un klinik semptomlarına bakıldığında yüksek ateş,öksürük, yorgunluk gibi birçok semptomu vardır. Yaşlılarda vekronik hastalıkları olanlarda bu hastalığın çok ağır geçtiği vesitokin fırtınası ile akut solunum sıkıntısı sendromu (ARDS) gibiciddi sonuçlara neden olduğu bildirilmektedir. Şu anda biliminsanları tarafından spesifik antiviral tedavi stratejisi bulunmayaçalışılmaktadır. Hidroksiklorokin, lopinavir/ritonavir, ribavirin,remdesivir ve favipiravir gibi çeşitli ilaçlar şu anda Dünya çapındaCOVİD-19 tedavisinde etkinliklerini ve güvenliklerini test etmekiçin klinik çalışmalarda uygulanmaktadır ve şimdiye kadar bazıumut verici sonuçlar elde edilmiştir. Bu derlemede, COVİD-19’akarşı potansiyel etkinliği olan ajanlar özet halinde sunulmaktadır.

🔖

Cite This Article

GÜLER, E. M., GÖKÇE, M. (2022). An Overview of COVID-19 Medicines in Current Guidelines. Bezmiâlem Science, Cilt: 8 - Sayı: 3, 44–49. https://ajindex.com/articles/464009

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Center JHCR. COVID-19 Map 2020. Available from: https:// coronavirus.jhu.edu/map.html
  2. T.C. Sağlık Bakanlığı. T.C Sağlık Bakanlığı Korona Tablosu 2020. Available from:
  3. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64-8
  4. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronavirusesdrug discovery and therapeutic options. Nature reviews Drug Discov 2016;15:327
  5. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a Review. JAMA 2020;323:1824-36
  6. T.C. Sağlık Bakanlığı. COVID-19 Erişkin Hasta Tedavisi. 2020. Available from: https://covid19.saglik.gov.tr/TR-66926/eriskinhasta-tedavisi.html p. 1-19
  7. T.C. Sağlık Bakanlığı. COVID-19. Çocuk Hasta Yönetimi ve Tedavisi. Available from: https://covid19.saglik.gov.tr/Eklenti/38596/0/covid19rehbericocukhastayonetimivetedavipdf.pdf 2020. p. 1-5
  8. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67-9
  9. Aguiar AC, Murce E, Cortopassi WA, Pimentel AS, Almeida MM, Barros DC, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 2018;8:459-64
  10. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75:1667-70
  11. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. J Virol 2005;2:69
  12. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001;20:137- 40
  13. Wang L. Cell Res. the press; 2019
  14. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis 2003;3:722-7
  15. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. Avaialble from: ClinicalTrials.gov. Home 2020
  16. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Ag